sur MIRA Pharmaceuticals (NASDAQ:MIRA)
MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit
MIRA Pharmaceuticals announced that new preclinical data on Ketamir-2 will be presented at the 18th Annual Pain Therapeutics Summit in Boston, MA on October 28-29, 2024. The data shows Ketamir-2 achieving a complete reversal of neuropathic pain in preclinical models.
The Summit is a notable forum for experts to discuss pain management innovations. MIRA's participation reveals its commitment to addressing unmet needs in neuropathic pain, a condition with limited treatments available.
Preclinical studies demonstrated Ketamir-2, an oral ketamine analog, to be effective in fully reversing neuropathic pain responses. These results point to Ketamir-2's promising potential as an innovative therapy with fewer side effects.
Dr. Itzchak Angel of MIRA, who will present the data, emphasized the groundbreaking nature of these findings, suggesting significant improvements over existing treatments.
MIRA is preparing to submit an IND application to the FDA by December 2024, with plans for human trials in 2025.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MIRA Pharmaceuticals